How would you treat a patient with metastatic urothelial carcinoma with early progression on maintenance immunotherapy?
If the patient received <2 months of immunotherapy, would you continue immunotherapy alone or transition to enfortumab monotherapy or EV+Pembro?
Community PollStarted
How would you treat a patient with urothelial carcinoma with early progression on maintenance immunotherapy?
25 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · City of Hope
Answered on
It would depend on the clinical scenario, specifically the disease volume, degree of progression, and whether the patient is deriving clinical benefit despite radiographic progression. Significant early progression in a patient with high disease volume/symptoms is a poor prognostic indicator and we ...
Join for free or sign in to see the full answer
Mednet Member
Medical Oncology · Aspirus UW Cancer Center
Answered on
Would continue and monitor by the measurable disease.
Join for free or sign in to see the full answer